CN115590013A

CN115590013A - Cryopreservation solution and cryopreservation method for natural killer cells and application of cryopreservation solution and cryopreservation method

Info

Publication number: CN115590013A
Application number: CN202110766427.2A
Authority: CN
Inventors: 焦顺昌; 张嵘; 卢社莲; 牛立超
Original assignee: Beijing Dingcheng Taiyuan Biotechnology Co ltd
Current assignee: Beijing Dingcheng Taiyuan Biotechnology Co ltd
Priority date: 2021-07-07
Filing date: 2021-07-07
Publication date: 2023-01-13
Anticipated expiration: 2041-07-07
Also published as: CN115590013B

Abstract

The invention provides a cryopreservation solution of natural killer cells, a cryopreservation method and application, and relates to the technical field of cell cryopreservation. The invention provides a frozen stock solution of natural killer cells, which does not contain serum and culture medium components and can be directly applied to clinic. The cryopreservation liquid is used for performing long-term cryopreservation on NK cells, and cell viability and phenotype are unchanged after two months of cryopreservation, so that the cryopreservation liquid has a specific protection effect on natural killer cells.

Description

Cryopreservation solution and cryopreservation method for natural killer cells and application of cryopreservation solution and cryopreservation method

Technical Field

The invention belongs to the technical field of cell cryopreservation, and particularly relates to a cryopreservation solution of natural killer cells, a cryopreservation method and application.

Background

Natural killer cells (NK cells) are an important component in natural immune cells, and unlike T cells, lack surface T Cell Receptors (TCRs) and do not induce graft-versus-host disease (GVHD) reactions, so NK cells are considered "off-the-shelf" cell therapy products, can be prepared frozen for use in advance, optimized and distributed according to the needs of multiple patients.

The freezing storage of cells, such as the freezing storage of various mammalian cells by using liquid nitrogen, is a method which is widely applied at present. The cell freezing and thawing process has some damage to all cells and tissues, and thus, effective techniques for preventing cell death and damage need to be developed.

Cryoprotectants fall into two categories: one is protective by penetrating into cells, such as glycerol, dimethyl sulfoxide, ethylene glycol, diethylamide, etc., and during freezing, the protective agent enters cells to prevent the concentration of intracellular electrolyte and other substances from increasing excessively to protect them; another additional class of non-penetrating protectants is hydroxyethyl starch, albumin, methyl cellulose, dextran40, and the like. However, some cryoprotectants, while protecting cells during slow freezing, also cause cytotoxicity, especially at room temperature.

At present, technical problems remain despite the existence of optimized cryopreservation protocols and published formulations in most research and medical fields. For example, the quality is poor after recovery, including the reduction of cell survival rate, apoptosis and necrosis of cells; an epigenetic change; loss of cellular function; alterations in gene expression and morphology; slow cell proliferation after recovery, etc. At present, no NK cell freezing solution which is specially used for NK cells and can be directly injected intravenously is available.

Disclosure of Invention

In view of the above, the present invention aims to provide a cryopreservation solution for natural killer cells, a cryopreservation method and applications thereof, wherein the cryopreservation solution can ensure long-term cryopreservation of NK cells, and the cell viability and phenotype are not changed during long-term storage.

In order to achieve the above object, the present invention provides the following technical solutions:

the invention provides a frozen stock solution of natural killer cells, which comprises the following raw materials in percentage by volume: 8 to 12 percent of DMSO, 0.2 to 3 percent of dextran, 5 to 15 percent of human serum albumin and 20 to 200IU/mL of IL-2.

Preferably, the dextran comprises dextran40 sodium chloride injection.

Preferably, the human serum albumin comprises human serum albumin intravenous infusion solution.

Preferably, the IL-2 comprises recombinant human interleukin-2 for injection.

Preferably, the raw material of the frozen stock solution also comprises 0.9% sodium chloride injection with the volume percentage content of 20-50%.

The invention also provides application of the cryopreservation liquid in long-term cryopreservation of NK cells.

The invention also provides a method for cryopreserving the NK cells for a long time, which comprises the following steps: placing natural killer cells in the frozen stock solution, and performing freezing by gradient cooling to-80 ℃.

Preferably, the frozen stock solution contains 2X 10 of the total amount of the frozen stock solution per mL ⁷ ～8×10 ⁷ And (4) natural killer cells.

Preferably, the freezing time is not less than 2 months.

The invention also provides a natural killer cell mixture capable of being directly injected, wherein the natural killer cell mixture comprises the frozen stock solution and natural killer cells.

Has the advantages that: the invention provides a frozen stock solution of natural killer cells, which does not contain serum and culture medium components and can be directly applied to clinic. According to the invention, the cryopreservation liquid is used for performing long-term cryopreservation on NK cells, and the cell viability and phenotype are not changed after two months of cryopreservation, so that the cryopreservation liquid has a specific protection effect on natural killer cells.

Drawings

FIG. 1 is a graph of the effect of IL-2 concentration in frozen stock solution on NK cell viability;

FIG. 2 shows the change in survival rate before cryopreservation and after resuscitation;

FIG. 3 is a graph showing the effect of IL-2 concentration in the frozen stock solution on the cell ratio, each term representing CD3 from the top to the bottom in this order ^- /CD56 ⁺ NK cells, CD16 in NK ⁺ Cells、CD3 ⁺ /CD56 ⁺ NKT cell, CD16 in NKT ⁺ Cell, CD3 ⁺ /CD56 ^- T cells and NK + NKT total cells;

FIG. 4 is a graph showing the change in cell ratio before cryopreservation and after recovery, each item showing CD3 sequentially from top to bottom ^- /CD56 ⁺ NK cells, CD16 in NK ⁺ Cell, CD3 ⁺ /CD56 ⁺ NKT cells, CD16 in NKT ⁺ Cell, CD3 ⁺ /CD56 ^- T cells and NK + NKT total cells;

FIG. 5 is a graph of the effect on target cell killing after resuscitation of NK cells cryopreserved with IL-2-containing cryopreserved medium, each item representing DLD-1, H358 and AGS in order from left to right;

FIG. 6 is the killing efficiency on target cells before cryopreservation and after resuscitation (E: T = 20;

FIG. 7 shows the cell viability change before and after NK cryopreservation;

FIG. 8 shows the viability change of NK-21-4 before cryopreservation and after resuscitation;

FIG. 9 shows the change in cell ratio before and after cryopreservation, each item showing CD3 in the order from top to bottom ^- /CD56 ⁺ NK cells, CD16 in NK ⁺ Cell, CD3 ⁺ /CD56 ⁺ NKT cell, CD16 in NKT ⁺ Cell, CD3 ⁺ /CD56 ^- T cells and NK + NKT total cells;

FIG. 10 shows the change in cell ratio before cryopreservation and after recovery, each item representing CD3 sequentially from top to bottom ^- /CD56 ⁺ NK cells, CD16 in NK ⁺ Cell, CD3 ⁺ /CD56 ⁺ NKT cell, CD16 in NKT ⁺ Cell, CD3 ⁺ /CD56 ^- T cells and NK + NKT total cells;

FIG. 11 shows the killing effect on tumor target cells before and after cryopreservation, each item representing DLD-1, H358 and AGS in order from left to right;

FIG. 12 is a graph of the change in killing of target cells before NK cells are cryopreserved and after resuscitation (E: T = 20;

FIG. 13 shows the cell viability change before and after cryopreservation;

FIG. 14 is a column showing the change in cell proportion before and after cryopreservationEach item in the graph represents CD3 from top to bottom in sequence ^- /CD56 ⁺ NK cells, CD16 in NK ⁺ Cell, CD3 ⁺ /CD56 ⁺ NKT cell, CD16 in NKT ⁺ Cell, CD3 ⁺ /CD56 ^- T cells and NK + NKT total cells;

FIG. 15 shows the killing efficiency (%) of target cells before and after cryopreservation, where each item in the bar graph shows DLD-1, H358 and AGS in order from top to bottom;

FIG. 16 is a bar graph of NK cell cryopreservation resuscitation rate;

FIG. 17 cell proportion changes before and after 2 months of cell cryopreservation, each item representing CD3 sequentially from left to right ^- /CD56 ⁺ NK cells, CD16 in NK ⁺ Cell, CD3 ⁺ /CD56 ⁺ NKT cell, CD16 in NKT ⁺ Cell, CD3 ⁺ /CD56 ^- T cells and NK + NKT total cells;

FIG. 18 is a graph of NK cell cryopreservation resuscitation killing change, each item in the bar graph representing DLD-1, H358 and AGS in order from left to right;

FIG. 19 is a photograph showing hemolysis after 3h incubation of different batches of samples, wherein Y12-20210628A, Y12-20210628B, Y12-20210628C and Y12-20210628D are sequentially shown from left to right from top to bottom;

FIG. 20 is a photograph of the bottom of the tube after centrifugation and incubation of the different batches of samples, wherein Y12-20210628A, Y12-20210628B, Y12-20210628C and Y12-20210628D are indicated from left to right in sequence from top to bottom.

Detailed Description

The volume percentage content of DMSO (Dimethyl Sulfoxide) in the frozen stock solution is preferably 8-10%, and most preferably 10%. The source of DMSO is not particularly limited in the present invention, and is preferably purchased from sigma (cat. No. d2650100ml, lot. # RNBJ 400).

The volume percentage content of the dextran in the freezing solution is preferably 0.5-1%, and more preferably 0.5%. The dextran of the present invention preferably comprises dextran40 sodium chloride injection. The source of the dextran is not particularly limited in the present invention, and is preferably obtained from Shandong-Tongzi pharmaceutical Co., ltd (national Standard H20065232).

The volume percentage content of the human serum albumin in the frozen stock solution is preferably 5-10%, and more preferably 10%. The human serum albumin has a protective effect on cryopreserved NK cells, and can improve the activity of the recovered NK cells and the killing capacity on target cells. The human serum albumin of the invention preferably comprises an intravenous infusion solution of human serum albumin. The human serum albumin is preferably purchased from Jettebelin (production batch: P100225458) and has the specification of 10 g/bottle (20 percent and 50 mL).

The concentration of IL-2 in the frozen stock solution is preferably 25 to 150IU/mL, more preferably 50 to 100IU/mL, and most preferably 50IU/mL. The IL-2 provided by the invention has a protection effect on the cryopreservation of NK cells. The IL-2 of the invention preferably comprises recombinant human interleukin-2 for injection. The invention relates to the recombinant human interleukin-2 (II) for injection ¹²⁵ Ala) is not particularly limited, and is preferably purchased from the Shuanglu pharmaceutical industry (national drug standardization S19991010).

The raw material of the freezing medium of the invention preferably also comprises sodium chloride injection with the volume percentage of 20-50% and 0.9%, more preferably 25-40%, and most preferably 29.5%. The 0.9% sodium chloride injection is preferably purchased from Shijiazhuang four-drug Co., ltd (national Standard H13023200).

The frozen stock solution provided by the invention aims at natural killer cells (NK cells) and does not contain a culture medium and serum, so that the clinical-level application requirement is met. In the embodiment of the invention, the cell freezing medium is used for freezing and storing the NK cells for more than 2 months, and the activity and the cell phenotype of the NK cells are not changed.

The invention also provides a preparation method of the frozen stock solution, which preferably comprises the following steps: the frozen stock solution is prepared in a sterile workbench at room temperature (18-26 ℃) in a dark place and is ready to use. And in the preparation, 0.9% NaCl injection, DMSO, dextran40 sodium chloride injection (Dextran 40), human albuminWhite blood transfusion solution (HSA) and recombinant human interleukin-2 (A) for injection ¹²⁵ Ala) were added sequentially, gently shaking and mixing well after each addition of one ingredient.

The invention also provides application of the frozen stock solution in long-term cryopreservation of NK cells.

The frozen stock solution of the present invention preferably contains 2X 10 of the active ingredient per mL of the frozen stock solution ⁷ ～8×10 ⁷ And (4) natural killer cells. The NK cells of the invention preferably further comprise washing before use, and the washing preferably comprises collecting the cells by using a 225mL centrifuge tube, centrifuging for 5min at 1200g, discarding the supernatant after centrifugation at room temperature, and washing twice by using sterile 0.9% sodium chloride injection. According to the invention, the NK cells are placed in the frozen stock solution and then subjected to gradient cooling, wherein the gradient is preferably-1 ℃/min. By using the method, the cryopreservation time of the NK cells is not less than 2 months, and the cell viability and phenotype are not changed after two months of cryopreservation.

The invention also provides a natural killer cell mixture capable of being directly injected, wherein the natural killer cell mixture comprises the frozen stock solution and natural killer cells. The proportion of the mixture of the invention is preferably the proportion of NK cells and frozen stock solution before freezing, but the mixture can be directly applied to clinic, such as intravenous injection or intraperitoneal injection, and the like before freezing or after thawing.

The following will explain in detail a natural killer cell cryopreservation solution, a cryopreservation method and applications provided by the invention with reference to examples, but they should not be construed as limiting the scope of the invention.

In the following examples of the present invention, the preparation method of each frozen stock solution was: at room temperature, preparing the frozen stock solution in a sterile workbench in a dark place, and preparing the frozen stock solution for use at present. 0.9% NaCl, DMSO, dextran40, HSA and IL-2 were added in this order, and after each addition of one ingredient, the mixture was gently shaken and mixed.

The NK cell cryopreservation method comprises the following steps: NK cells are washed, added with freezing solution and then cooled down in a gradient manner to-80 ℃ (-1 ℃/min).

Reagent for test

(1) Human serum albumin iv infusion solution, 10 g/vial (20%, 50 mL), jerlbilin, manufacturing lot No.: p100225458.

(2)Dimethyl Sulfoxide，sigma，Cat.No.D2650100ml，Lot.#RNBJ400。

(3) 0.9% sodium chloride injection, national Standard H13023200, shijiazhuang Siyao GmbH.

(4) Dextran40 sodium chloride injection (Dextran 40, concentration 6%), national Standard H20065232, shandong Qi Du pharmaceutical Co., ltd.

(5) Recombinant human interleukin-2 (for injection) ¹²⁵ Ala), national drug standard S19991010, double aigret pharmaceutical industry.

Example 1

Effect of IL-2 on cryopreservation of NK cells derived from PBMC

(1) Effect on cell viability

(1) Viability Change of cryopreserved cells at 4 weeks

Cultured natural killer cells, harvested on day 16, cryopreserved with a cryopreservation solution (10% (v/v, same below) DMSO +16.7%6% Dextran40 + N IU/mL IL-2+73.3%0.9% NaCl injection), where N represents 0, 50, 100, 150, 200, and 250; then, the cells were recovered in a selected portion after freezing for 4 weeks, and the cell viability was measured.

After the cells are frozen and stored for 4W, the viability is reduced to different degrees compared with the cells before the cells are frozen and stored, wherein the cell viability of the frozen and stored liquid with the IL-2 content of 50IU/mL is the highest, and the cell viability (79.7%) of the cells after the cells are frozen and stored for 4W by liquid nitrogen is 91% (figure 1) of the cell viability (87.9%) before the cells are frozen and stored.

(2) Cell viability Change in frozen 5 months

After the NK cells are cryopreserved for 5 months by using the method, the cell viability is recovered and detected, the cell viability is reduced, and the difference among all groups is small (figure 2).

(2) Effect on cell phenotype

(1) Cryopreserved 4-week cell phenotypic changes

The cultured NK cells were finally cultured in 3 bags of 2.5L cell suspension per bag. On day 16, the cells were harvested and frozen in (10%)DMSO +16.7% by 6% Dextran 40% N IU/mL IL-2+73.3% by 0.9% NaCl injection), where N represents 0, 50, 100, 150, 200 and 250; then, selecting partial cells to recover after freezing for 4 weeks, detecting cell phenotype, slightly reducing the NK cell proportion after 3 times of freezing recovery compared with that before freezing, and ensuring that the NK proportion detected by each freezing solution group added with IL-2 is not greatly different. CD16 in NK ⁺ The proportion of cells decreases. The NKT cell ratio is increased compared with that before freezing. CD16 in NKT ⁺ The cell proportion is reduced, and no obvious difference exists among groups. The proportion of T cells is increased. The overall percentage NK + NKT content was slightly reduced with no significant difference (figure 3).

(2) Cell phenotype changes by cryopreservation for 5 months

After the cells are frozen and stored for 5 months and revived by the method, the phenotype of the cells is generally shown as follows: NK cell proportion was slightly elevated, 50IU/mL and 100IU/mL CD16 in IL-2 group NK ⁺ Slightly increased cells, slightly increased NKT cell proportion, slightly decreased T cell proportion, and slightly increased NK + NKT total cells. The differences between the different IL-2 dose groups were small (FIG. 4).

(3) Effect on killing of target cells

(1) Killing of target cells by cryopreservation for 4 weeks

The same culture and grouping and cryopreservation of NK cells as in (2) were performed.

The analysis shows that the kill rate of the frozen stock solution containing 150IU/mL IL-2 to DLD-1 is 69%, and the effect is best. The killing efficiency to H358 is not obviously different between 50/100/150IU/mL IL-2 groups and is about 40 percent. The killing of AGS cells was reduced from 52.8% before freezing to about 10% (FIG. 5).

(2) Killing target cells by cryopreservation for 5 months

After 5 months of cryopreservation of NK cells of PBMC20200331B-5 batch, killing of the target cells by the cells was resuscitated and detected, killing efficiency of each group to the target cells was reduced to different degrees, and the IL-2-containing cryopreservation solution group had better killing effect on the target cells than the IL-2-free cryopreservation solution group, wherein the IL-2 group added with 200IU/mL had the best killing effect on the target cells (FIG. 6).

The IL-2 group added in the frozen stock solution has stronger killing effect on target cells than the NK cells frozen and stored without the IL-2 group after recovery, which indicates that the IL-2 in the frozen stock solution has a protective effect on the freezing storage of the NK cells.

Example 2

Cryopreservation effects of HSA on PBMC-derived NK cells

Cryopreserving NK cells using cryopreserved solution (12.5, 25, 37.5 and 50% by volume DMSO +16.7%6% 10% HSA +73.3% -23.3%0.9% NaCl injection); the HSA concentration was varied from 0 to 10% in 5 steps. After the cells are frozen for 4 weeks, the cells are recovered, and the killing of NK cells on target cells and the activity of NK are detected, so that the freezing effect of the frozen stock solution containing HSA is comprehensively evaluated through phenotype.

(1) Effect on cell viability

(1) Cell viability Change at 4 weeks of cryopreservation

20200331 batch-5-NK cell viability map 7 shows before and after cryopreservation, cell viability before cryopreservation was 86.0%, cell viability was recovered after 28 days of cryopreservation, cell viability of frozen stock solution without HSA was 75.8%, and cell viability was reduced by 12%. The frozen stock solution containing HSA has a remarkable effect of protecting cells from freezing, and the frozen stock solution containing 5% HSA has a cell viability of preferably 80.3% after recovery and 93.4% before freezing.

(2) Cell viability Change in frozen 5 months

PBMC20200331B-5 batch-NK cells after 5 months of cryopreservation were resuscitated for cell viability, which was decreased by varying degrees, by 10% of the HSA cryopreservation group with highest cell viability followed by 2.5% of the group, and 5% of the HSA group (FIG. 8).

(2) Effect on cell phenotype

(1) Cryopreserved 4-week cell phenotypic changes

Flow-through detection of cellular phenotype, CD3, before and after cryopreservation ^- CD56 ⁺ The NK cell ratio was not significantly different, and the NK ratio before freezing was 97.88%, the HSA-supplemented frozen stock solution group was 96.5% except for 7.5% in the HSA group, and the rest was 97.5% or more in most cases. CD16 in NK after cryopreservation ⁺ The cell proportion is reduced, and CD16 in NK before freezing ⁺ The proportion of cells was 97.43%. Frozen stock solution without HSA, CD16 in NK after being frozen and stored for 28 days for recovery ⁺ The proportion of cells was 65.95%, and HSA was added to the cells for cryopreservationCD16 in NK after recovery of most of the solutions (except plus 7.5% HSA group) ⁺ The percentage value of the cells is higher than that of the group without HSA. Wherein CD16 in NK after cryopreservation ⁺ The group with the highest cell ratio was the group to which 10% HSA was added. The proportion of NKT cells is mostly not obviously changed before and after the cells are frozen, the proportion before freezing is 1.29 percent, and the increase of 7.5 percent of the groups is 2.3 percent, and the proportion of other groups is about 1.4 percent. CD16 in NKT ⁺ The proportion of the frozen cells is reduced, 45.96 percent before freezing, 17.66 percent of the group without HSA after freezing and 14 to 15 percent of the rest groups with HSA. CD3 ⁺ CD56 ^- The T cell ratio is not much different before and after cryopreservation, 0.68% before cryopreservation, 0% after cryopreservation, 2.5%,5%,10% HSA group T cell ratio between 0.6% and 0.8%. T cells were slightly elevated at 1.06% in the HSA-containing group at 7.5%. The proportion of NK + NKT cells was not significantly different before and after the whole cryopreservation, and was all above 99% (FIG. 9).

(2) Cell phenotype changes by cryopreservation for 5 months

The phenotype of the PBMC20200331B-5 cells after 5 months of recovery from cryopreservation is generally shown in FIG. 10: slightly elevated NK cell proportion, 2.5% and 5% CD16 in HSA group NK ⁺ Slightly increased cells, slightly increased NKT cell proportion, slightly decreased T cell proportion, and slightly increased NK + NKT total cells. The difference between different HSA dose groups was small.

(3) Effect on target cell killing

(1) Killing of target cells by cryopreservation for 4 weeks

PBMC20200331B-5 batches NK D cultured by mononuclear cells derived from peripheral blood after recovery for 16 days and 28 days of cryopreservation has killing effect on human colorectal adenocarcinoma epithelial cells (DLD-1), human non-cell lung cancer cells (H358) and human gastric adenocarcinoma cells (AGS) (ratio of effector cells to target cells is 20. The percentage of cells frozen in the HSA frozen stock solution was 10% DMSO +1% Dextran40 + N% after 4 weeks, the difference in the killing effect of NK cells on target cells in different frozen stock solution groups after recovery is shown in FIG. 11, and the killing effect of NK cells in the frozen stock solution groups with addition of 2.5%,5% and 10% HSA was higher than that in the group without HSA. The percentage of 10% by weight of the HSA cryopreservation solution group that resulted in the highest killing efficiency of target cells after recovery of cryopreserved NK cells was determined.

(2) Killing target cells by freezing for 5 months

As shown in FIG. 12, the killing efficiency of NK cells against target cells after 5 months of recovery from cryopreservation was reduced in each of the cryopreservation groups, and the killing efficiency of cells against target cells was higher in the frozen stock solution group containing 5% HSA and the frozen stock solution group containing 10% HSA than in the frozen stock solution group containing no HSA, wherein the killing efficiency of target cells was the highest in the frozen stock solution group containing 5% HSA and the frozen stock solution group containing 10% HSA.

After HSA is added into the frozen stock solution, the frozen stock NK cells are protected, and the activity of the recovered NK cells and the killing capacity of the target cells can be improved.

Example 3

(1) Four-factor four-level orthogonal experimental design

Concentration interactions between the various groups of components of the frozen stock solution may exist, and therefore orthogonal experiments between different concentration levels of four components, DMSO, dextran40, HSA and IL-2, in the frozen stock solution were designed, and 0.9% NaCl injection was added to the frozen stock solution to achieve a constant volume. The concentration levels of the factors are shown in Table 1, the concentration range of DMSO is 4% -10%, the concentration range of Dextran40 is 0.5% -3%, the concentration range of HSA is 2.5% -10%, and the concentration range of IL-2 is 25 IU/mL-200 IU/mL. The experiment L16 (44) included a total of 16 combinations, the details of which are shown in table 2.

TABLE 1 Quadrature experiment four-factor four-level meter

TABLE 2 L16 (4) ⁴ ) Orthogonal table

(2) Effect on cell viability

The cell viability value of NK cells before freezing is 86.3%, the cell viability of each group is reduced to different degrees after 28-day recovery, the cell viability of C10, C12 and C13 groups is 80.4%,86.3% and 85.3%, respectively, and the difference between the three groups has no statistical significance (P is more than 0.05) (FIG. 13). However, C10 kills target cells less efficiently.

(3) Effect on cell phenotype

CD3 in NK cells after cryopreservation ^- /CD56 ⁺ The proportion of NK cells is 80.96 percent before freezing, and the proportion of NK cells in groups C10, C12 and C13 is reduced after freezing recovery, and is 77.91 percent, 78.41 percent and 76.30 percent respectively. CD16 in NK ⁺ The cell proportion is greatly reduced from 98.32 percent before freezing storage, and CD16 in NK of C10, C12 and C13 groups after the thawing of freezing storage ⁺ The cell proportion was reduced to 41.14%,29.71% and 44.90%, respectively. The proportion of NKT cells is slightly increased after the cryopreservation, 12.58 percent before the cryopreservation and 10 to 15 percent after the cryopreservation. CD16 in NKT ⁺ The cell proportion is reduced from 30.76% before freezing to about 17%. The T cell proportion is slightly increased from 6.43% before freezing to about 8% (C10, C12, C13). The total cell ratio of NK and NKT is slightly reduced to 93.54% before freezing, and the cell ratio of NK and NKT in three groups of C10, C12 and C13 after freezing recovery is respectively 92.12%,91.94% and 91.59%, and no obvious difference exists among the groups (figure 14).

(4) Effect on cell killing

Killing efficiency on target cells before and after NK cell cryopreservation (figure 15) indicates: c10 groups (A3B 2C4D 3: 8% DMSO +1%Dextran 40+10% HSA +100IU/mL IL-2), C12 (A3B 4C2D1, i.e. 8% DMSO +3% Dextran40 +5% HSA 25IU/mL IL-2), C13 (A4B 1C4D2, i.e. 10% DMSO +0.5% Dextran40 +10% HSA +50IU/mL IL-2) the killing efficiency of the target cells is highest for three groups. The killing efficiency of NK to DLD-is 78% before freezing, and the killing efficiency of three groups of frozen recovery cells C10, C12 and C13 to DLD-1 is 65%,60.67% and 70.33%, respectively. The killing efficiency of the NK cells to H358 before cryopreservation is 73%, and the killing efficiency of the cryopreserved resuscitation cells C10, C12 and C13 to H358 is 34%,33% and 42% respectively. The killing efficiency of NK cells to AGS before cryopreservation is 40%, and the killing efficiency of cryopreserved recovery cells C10, C12 and C13 to AGS is 8%,8% and 11% respectively.

That is, the killing efficiency of the C13 group on the cells was the highest, and the killing of the C12 group on the target cells was slightly lower than that of C13.

Example 4

Verification test of cell frozen stock solution

Cultured NK cells, 10% DMSO +0.5% Dextran40 +10% cells frozen with HSA +50IL-2 with frozen stock solution, resuscitated after 4 months of frozen stock, examined for cell viability, phenotype and killing.

(1) Effect on cell viability

Two months after the NK cells were cryopreserved, no change in cell viability was detected (fig. 16).

(2) Effect on cell phenotype

After two months of NK cryopreservation, cell phenotype was detected by flow (FIG. 17), the proportion of NK cells was slightly increased, and CD16 in NK cells ⁺ Slightly increased cell proportion, decreased NKT cell proportion, CD16 in NKT ⁺ The cell proportion is reduced, the T cell proportion is slightly increased, and the NK + NKT cell proportion has no obvious change.

(3) Effect on cell killing

After the NK cells are frozen and stored for two months, the killing effect is shown in figure 18, and the killing effect on DLD-1 target cells is unchanged; the killing rate of the H358 target cells is reduced to 43.73 percent from 48.59 percent before the cryopreservation, and the killing rate is 90 percent before the cryopreservation; the killing efficiency of AGS target cells is reduced to 30.75% from 38.52% before cryopreservation, and the killing efficiency is 80% before cryopreservation.

In conclusion, after the NK cells are frozen and preserved by the cell freezing solution for two months, the cell viability and the phenotype are not changed, and the killing efficiency of the NK cells on target cells DLD-1, H358 and AGS is respectively 100 percent, 90 percent and 80 percent before freezing and preserving.

Example 5

Hemolysis experiment of NK frozen stock solution

The test was carried out by in vitro tube visual observation. If the result of visual observation shows that the test tube added with the frozen stock solution has clear red compared with the negative control tube or the result is difficult to judge, the further judgment is carried out by spectrophotometry.

1. Preparation of 2% erythrocyte suspension

5mL of peripheral blood was transferred to a 15mL centrifuge tube, 10mL of physiological saline was added thereto, the mixture was shaken up, centrifuged at 2500rpm for 5min, and the supernatant was discarded. Adding 10mL of 0.9% sodium chloride injection, centrifuging again, repeatedly washing the red blood cells for 3-4 times until the supernatant is colorless and transparent. The red blood cells obtained were mixed with physiological saline to prepare a 2% red blood cell suspension for testing.

2. Test procedure

Taking 7 glass test tubes of 10mL, numbering the test tubes, sequentially arranging the test tubes on a test tube rack, sequentially adding 2% erythrocyte suspension and physiological saline according to the proportioning in the table 3, then adding different amounts of frozen stock solution into test tubes of 1-5, adding 2.0mL of physiological saline into a test tube of No. 6 as a negative blank control, and adding 2.0mL of sterilized injection water into a test tube of No. 7 as a hemolytic positive control.

After adding liquid into each test tube, mixing uniformly, immediately placing the test tubes in a water bath box at 37 +/-0.5 ℃ for incubation for 3h (the opening of the flow tube is sealed by a sealing film to prevent the liquid from evaporating).

TABLE 3 hemolytic test tube and sample preparation

3. Frequency and method for detecting various indexes

(1) In vitro test tube visual inspection

All tubes were observed at time points 15min, 30min, 45min, 1h, 2h, 3h after addition of the solution, for a total of 6 times.

Observing hemolysis and agglutination of blood at each time point, smoothly taking out the test tube from the water bath box after 3h incubation (37 ℃), and taking pictures; followed by centrifugation at 1500rpm for 10min and photography.

(2) Spectrophotometric frequency and method

When the result of visual observation shows that the test tube added with the sample solution has clear red color or the result is difficult to judge compared with the negative control tube. All tubes were observed.

After centrifugation at 1500rpm for 10min, the supernatant was placed in a 96-well plate, and 200. Mu.L of each well was added to each tube, and the OD value of each well was read in a microplate reader at 545nm in the presence of sterile water for injection as a blank. The OD value of each test tube was averaged to calculate the hemolysis rate.

After 3h incubation, the test tube was taken out from the water bath tank, placed in a test tube rack, photographed (fig. 19), and photographed again after centrifugation (fig. 20), and it was observed that in test tubes nos. 1 to 6, red blood cells were all settled, and the supernatant was colorless and clear, indicating that no hemolysis occurred.

There was no reddish-brown or reddish-brown flocculent precipitate in the supernatant liquid, no red blood cell coagulation, indicating no clotting. In the negative control group No. 6, no hemolysis and coagulation occurred. In the positive test tube No. 7, hemolysis occurred. The above results show that, under the test conditions, the frozen stock solution does not cause hemolysis and blood coagulation, and the frozen stock solution can be used for blood return transfusion.

The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and amendments can be made without departing from the principle of the present invention, and these modifications and amendments should also be considered as the protection scope of the present invention.

Claims

1. The cryopreservation solution for the natural killer cells is characterized by comprising the following raw materials in percentage by volume: 8 to 12 percent of DMSO, 0.2 to 3 percent of dextran, 5 to 15 percent of human serum albumin and 20 to 200IU/mL of IL-2.

2. The cryopreservation solution of claim 1, wherein the dextran comprises dextran40 sodium chloride injection.

3. The cryopreservation liquid of claim 1, wherein the human serum albumin comprises an intravenous infusion solution of human serum albumin.

4. The cryopreservation liquid of claim 1, wherein the IL-2 comprises recombinant human interleukin-2 for injection.

5. The cryopreservation liquid as claimed in claim 1, wherein the raw material of the cryopreservation liquid further comprises 20-50% by volume of 0.9% sodium chloride injection.

6. Use of the cell cryopreserved solution according to any one of claims 1 to 5 for cryopreserving NK cells for a long period of time.

7. A method for cryopreserving NK cells for a long time, comprising the steps of: placing natural killer cells in the cryopreservation solution of any one of claims 1 to 5, and performing cryopreservation by gradient cooling to-80 ℃.

8. The method of claim 7, wherein each mL of said frozen stock solution comprises 2 x 10 ⁷ ～8×10 ⁷ And (4) natural killer cells.

9. The method of claim 7, wherein the freezing time is not less than 2 months.

10. A natural killer cell mixture capable of being directly injected, comprising the cryopreservation solution of any one of claims 1 to 5 and natural killer cells.